AstraZeneca to invest $2bn in Summit Therapeutics

Under the terms of the deal, AstraZeneca will buy newly-issued equity in the New York-listed oncology specialist, giving it rights equivalent to around 12% of Summit’s common stock, or around 10.6% on a fully diluted basis.The tie-up will see the companies collaborate on a series of studies into th…